Abingdon HealthABDXF +8.93%49 Days Payable is 128.63 as of Dec. 2025, which is 23% below its 10-year median of 167.49. GuruFocus rates ABDXF with a GF Score™ of 49/100 and a GF Value™ of $0.21 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Abingdon Health ranks better than 71.73% on this metric.
The historical rank and industry rank for Abingdon Health's Days Payable or its related term are showing as below:
ABDXF'
s Days Payable Range Over the Past 10 Years
Min: 53.28 Med: 167.49 Max: 571.59
Current: 136.17
During the past 8 years, Abingdon Health's highest Days Payable was 571.59. The lowest was 53.28. And the median was 167.49.
ABDXF's Days Payable is ranked better than 71.73% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 68.87
vs ABDXF: 136.17
Abingdon Health's Days Payable
declined
from Dec. 2024 (139.16) to Dec. 2025 (128.63).
It may suggest that Abingdon Healthaccelerated paying its suppliers.
Abingdon Health Days Payable Related Terms
Abingdon Health Days Payable Historical Data
* Premium members only.
The historical data trend for Abingdon Health's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Abingdon Health's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abingdon Health Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Abingdon Health's Days Payable distribution charts can be found below:
* The bar in red indicates where Abingdon Health's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Abingdon Health's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abingdon Health (ABDXF) has a Days Payable of 128.63 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Abingdon Health and its competitors. This is 23% below median its historical median of 167.49. Over the past decade, Abingdon Health's Days Payable has ranged from 53.28 to 571.59. According to the industry distribution chart, Abingdon Health ranks #54 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 28.3%.
Is Abingdon Health's Days Payable too high?
Abingdon Health's current Days Payable of 128.63 is 23% below median its 10-year median of 167.49. Over the past 10 years, this metric has ranged from a low of 53.28 to a high of 571.59. The Medical Diagnostics & Research industry median Days Payable is 68.87. Abingdon Health's value of 128.63 is 86.8% above this industry median. Based on the distribution chart, Abingdon Health ranks #54 out of 191 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Abingdon Health has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abingdon Health's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Abingdon Health ranks #54 out of 191 companies for Days Payable. This puts Abingdon Health in the upper half of its industry. The industry median Days Payable is 68.87. Abingdon Health's value of 128.63 is 86.8% above this benchmark. Historically, Abingdon Health's own Days Payable has ranged from 53.28 to 571.59 over the past decade. While the company's 10-year median is 167.49 vs. the industry median of 68.87, Abingdon Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 68.87, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abingdon Health's current Days Payable of 128.63 is 86.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Abingdon Health and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 68.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abingdon Health's current Days Payable is 128.63, which is 23% below median its own 10-year median of 167.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abingdon Health stock overvalued right now?
Based on GuruFocus' analysis, Abingdon Health (ABDXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.21, compared to a current price of $0.15 — trading 27.4% below its estimated fair value. The current Days Payable is 128.63, which is 23% below median its 10-year median of 167.49 and 86.8% above the Medical Diagnostics & Research industry median of 68.87. Abingdon Health's overall GF Score™ is 49/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Abingdon Health (ABDXF), the current Days Payable is 128.63 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abingdon Health (ABDXF) Overvalued in 2026?
Based on GuruFocus' analysis, Abingdon Health stock appears to be undervalued.
The current stock price of $0.15 is trading 27.4% below its estimated GF Value™ of $0.21.
GuruFocus considers Abingdon Health to be Modestly Undervalued.
Key valuation signals for ABDXF:
Days Payable: 128.63 (23% below median its 10-year median of 167.49)
GF Value™: $0.21 vs. price of $0.15 (27.4% below fair value)
Industry Position: 86.8% above the Medical Diagnostics & Research median (#54 of 191)
No single metric tells the full story. See the ABDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.
49GF Score
Get the complete analysis for ABDXF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABDXF has been successfully added to your 
